<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Children with <z:hpo ids='HP_0001067'>neurofibromatosis</z:hpo> type 1 (NF1) are at increased risk of developing benign and <z:e sem="disease" ids="C1698088" disease_type="Neoplastic Process" abbrv="">malignant solid tumors</z:e> as well as <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e>, including de novo juvenile <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo>, <z:mp ids='MP_0004026'>monosomy</z:mp> 7 syndrome, and <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The <z:mpath ids='MPATH_458'>normal</z:mpath> NF1 allele is frequently deleted in the bone marrow cells from NF1 patients with <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e>, suggesting a pathogenic role in primary <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">leukemogenesis</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>The authors report <z:mp ids='MP_0004026'>monosomy</z:mp> 7 <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) as a second malignant <z:hpo ids='HP_0002664'>neoplasm</z:hpo> (SMN) in five children with <z:hpo ids='HP_0003745'>sporadic</z:hpo> NF1, the results of molecular analysis for NF1 and ras alterations in their bone marrow, and summarize their experience with SMNs in pediatric patients with NF1 </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: <z:mp ids='MP_0004026'>Monosomy</z:mp> 7 MDS was diagnosed as an SMN in five children with NF1 by morphologic and cytogenetic studies of bone marrow specimens </plain></SENT>
<SENT sid="4" pm="."><plain>DNA extracted from these malignant bone marrows was analyzed for allelic loss at the NF1 locus and for the presence of ras mutations </plain></SENT>
<SENT sid="5" pm="."><plain>The Children's Hospital of Philadelphia (CHOP) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> Registry was also reviewed to estimate the incidence of SMNs in pediatric NF1 patients </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Bone marrow specimens from four patients retained constitutional heterozygosity at the NF1 locus; one specimen was uninformative </plain></SENT>
<SENT sid="7" pm="."><plain>There was no evidence of activating ras mutations </plain></SENT>
<SENT sid="8" pm="."><plain>The risk of an SMN was approximately 11% among the 64 NF1 registrants with primary <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> in the CHOP registry, but was 75% (6 of 8) among patients treated for a pediatric <z:e sem="disease" ids="C0751364" disease_type="Neoplastic Process" abbrv="">embryonal cancer</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: Children with NF1 are susceptible to the development of malignant myeloid disorders both as a primary event and as an SMN </plain></SENT>
<SENT sid="10" pm="."><plain>Additional molecular genetic analysis is necessary to determine if the NF1 gene is inactivated by <z:hpo ids='HP_0001428'>somatic mutation</z:hpo> in these secondary <z:hpo ids='HP_0001909'>leukemias</z:hpo> </plain></SENT>
</text></document>